AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneronnews2025-03-21T15:17:54+00:00March 21st, 2025|Endpoints News|
Paratek to acquire Optinose and its nasal spray Xhancenews2025-03-20T11:00:54+00:00March 20th, 2025|Endpoints News|
Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleternews2025-03-20T10:31:29+00:00March 20th, 2025|Endpoints News|
Roche inks $1B+ biobucks deal with Oxford BioTherapeutics for new antibody cancer targetsnews2025-03-19T11:05:26+00:00March 19th, 2025|Endpoints News|
Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drugnews2025-03-19T11:00:13+00:00March 19th, 2025|Endpoints News|
AstraZeneca inks deal with Alteogen for subcutaneous cancer drugsnews2025-03-17T19:40:49+00:00March 17th, 2025|Endpoints News|
Otsuka’s Taiho buys Swiss startup Araris with three ADCs nearing the clinicnews2025-03-17T11:30:33+00:00March 17th, 2025|Endpoints News|
AstraZeneca to buy cell therapy startup EsoBiotec for $425M upfrontnews2025-03-17T10:33:40+00:00March 17th, 2025|Endpoints News|
MeiraGTx partners with cryptic AI startup Hologen to advance Parkinson’s gene therapynews2025-03-13T15:32:22+00:00March 13th, 2025|Endpoints News|
Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companiesnews2025-03-13T14:50:24+00:00March 13th, 2025|Endpoints News|
